REGEN v ESTAR: Consequences for Patent Practioners

Sodium citrate content unknown

On 18 January 2019 we received our first patents trial judgment of the year in Regen v Estar Medical and ors [2019] EWHC 63 (Pat) (bailii). The trial itself took place over 5 days in June 2018. The claim was brought by Regen Lab against Estar Medical, who it accused of infringing its European Patent (UK) No. EP 2073862.

Regen describes itself as “a global leader in products for autologous regenerative medicine based on freshly prepared platelet rich plasma” whereas Estar considers itself more of a “world leader in Platelet-Rich Plasma (PRP) and autologous cell therapy technologies“: it would seem inevitable that there would be some bad blood between them.… Read more...